{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:56:58Z","timestamp":1790661418565,"version":"4.1.0"},"reference-count":68,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Human Ezrin Peptides (HEPs) are inhibitors of expression of IL-6 and other inflammatory cytokines, amplifiers of adaptive B cell and T cell immunity and enhancers of tissue repair. The mutation stable C-terminus of HIV gp120, mimics 69% of the \u201cHep-receptor\u201d, a zipped \u03b1-helical structure in the middle of the \u03b1 domain of human ezrin protein. Synthetic peptides homologous to the Hep-receptor of ezrin of five to fourteen amino acids, activate anti-viral immunity against a wide range of viruses (HIV, HCV, herpes, HPV, influenza and other human respiratory viruses). Human Ezrin Peptide One (HEP1) TEKKRRETVEREKE (brand name Gepon, registered for human use in Russia from 2001) is a successful treatment for opportunistic infections in HIV-infected patients. That treats HEP1and prevents mucosal candidiasis, herpes zoster outbreaks and infection-induced chronic diarrhea. There are clinical publications in Russian on the successful treatments of chronic recurrent vaginal candidiasis, acute and chronic enterocolitis and dysbacteriosis, which are accompanied by normalization of the mucosal microbiome, and the decline or disappearance of inflammation. HEP1 is also an effective treatment and prevention for recurrent inflammation and ulceration in the stomach, duodenum and colon. HEP1 and RepG3 GEKKRRETVEREGG (a derivative of HEP1) have been used successfully as an inhaled spray peptide solution to treat a small number of human volunteers with mild-to-moderate COVID, resulting from SARS-CoV-2 infection, based on earlier successes in treating acute viral respiratory disease with inflammatory complications. Ezrin peptides seem to correct a dysregulation of innate immune responses to SARS-CoV-2. They are also adjuvants of B cell adaptive immunity and increase antibody titres, resulting in protection from lethal virus infection of mice. In a clinical study in Moscow, orally administered HEP1 was shown to enhance antibody-titres produced in response to hepatitis-B vaccination. These very preliminary but promising results with ezrin peptide treatment of COVID must be replicated in large-scale randomised placebo controlled clinical studies, to be verified.<\/jats:p>","DOI":"10.3390\/ijms222111688","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T23:51:36Z","timestamp":1635465096000},"page":"11688","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ezrin Peptide Therapy from HIV to COVID: Inhibition of Inflammation and Amplification of Adaptive Anti-Viral Immunity"],"prefix":"10.3390","volume":"22","author":[{"given":"Rupert D.","family":"Holms","sequence":"first","affiliation":[{"name":"Newal R&D Ltd., London NW1 7SX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravshan I.","family":"Ataullakhanov","sequence":"additional","affiliation":[{"name":"Institute of Immunology, Ministry of Health of the Russian Federation, 115478 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"ref_1","unstructured":"Solovev, A.M. (2003). Conservative Therapy of Lesions caused by Papiloma Virus (HPV). Prescr. Physician, 22\u201326. (In Russian)."},{"key":"ref_2","first-page":"61","article-title":"Promising treatment for recurrent vulvovaginal candidiasis","volume":"13","author":"Kulikov","year":"2020","journal-title":"Meditinsky Sov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1615\/CritRevImmunol.2015012327","article-title":"The ezrin-radixin-moesin family of proteins in the regulation of B-cell immune response","volume":"35","author":"Pore","year":"2015","journal-title":"Crit. Rev. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.4049\/jimmunol.1201292","article-title":"Spatial Coupling of JNK Activation to the B Cell Antigen Receptor by Tyrosine-Phosphorylated Ezrin","volume":"190","author":"Parameswaran","year":"2013","journal-title":"J. Immunol."},{"key":"ref_5","first-page":"8","article-title":"Dependence of immune-adjuvant action of immune-modulator Gepon on peptide structure","volume":"6","author":"Katlinskii","year":"2002","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_6","first-page":"13","article-title":"Immuno-adjuvant properties of synthetic peptides derived from the hinge region of ezrin","volume":"6","author":"Holms","year":"2002","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_7","first-page":"23","article-title":"Anti-viral activity of Gepon and its structural homologues in human cell culture infected with encephalomyocarditis virus","volume":"6","author":"Katlinskii","year":"2002","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_8","first-page":"26","article-title":"Synthetic peptides mimicking the hinge region of human ezrin have anti-viral activity in cell culture infected with encephalomyocarditis virus","volume":"6","author":"Holms","year":"2002","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_9","first-page":"10","article-title":"Protective Vaccination against Hepatitis B in Children with Malignant Tumours","volume":"4","author":"Shamsheva","year":"2003","journal-title":"Child. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/jmv.25948","article-title":"Elevated interleukin-6 and severe COVID-19: A meta-analysis","volume":"92","author":"Aziz","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.chom.2021.05.004","article-title":"Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19","volume":"29","author":"Lowery","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.chom.2021.06.018","article-title":"An aberrant inflammatory response in severe COVID-19","volume":"29","author":"Merad","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hsu, A.C.-Y., Wang, G., Reid, A.T., Veerati, P.C., Pathinayake, P.S., Daly, K., Mayall, J.R., Hansbro, P.M., Horvat, J.C., and Wang, F. (2020). SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated by Spike-antagonistic peptide and FDA-approved ER stress and MAP kinase inhibitors in vitro. bioRxiv.","DOI":"10.1101\/2020.09.30.317818"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Patra, T., Meyer, K., Geerling, L., Isbell, T.S., Hoft, D.F., Brien, J., Pinto, A.K., Ray, R.B., and Ray, R. (2020). SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1009128"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"102295","DOI":"10.1016\/j.isci.2021.102295","article-title":"SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway","volume":"24","author":"Campbell","year":"2021","journal-title":"iScience"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1016\/S2665-9913(20)30287-3","article-title":"The conundrum of interleukin-6 blockade in COVID-19","volume":"2","author":"Campochiaro","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2213-2600(20)30600-7","article-title":"Assessing the importance of interleukin-6 in COVID-19","volume":"9","author":"Chen","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41577-021-00553-8","article-title":"Is IL-6 a key cytokine target for therapy in COVID-19?","volume":"21","author":"Simon","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMe2103108","article-title":"Interleukin-6 Receptor Inhibition in Covid-19\u2014Cooling the In-flammatory Soup","volume":"384","author":"Rubin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cell.2021.02.029","article-title":"COVID-19 and the human innate immune system","volume":"184","author":"Schultze","year":"2021","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"ref_22","unstructured":"Holms, R.D., and Ataullakhanov, R.I. (2021). Ezrin-Derived Peptides and Uses. (2100996.4), UK Patent Application No."},{"key":"ref_23","unstructured":"Holms, R.D., Bessler, W.G., Konopleva, M.V., and Ataullakhanov, R.I. (2021, August 13). Review of Russian Ezrin Peptide Treatment of Acute Viral Respiratory Disease and Virus Induced Pneumonia; A Potential Treatment for COVID-19. Available online: https:\/\/www.researchgate.net\/publication\/340600041_Review_of_Russian_ezrin_peptide_treatment_of_acute_viral_respiratory_disease_and_virus_induced_pneumonia_a_potential_treatment_for_covid-19."},{"key":"ref_24","unstructured":"Holms, R.D., and Ataullakhanov, R.I. (2021). Review of a Potential Cure for COVID with Human Ezrin Peptides: An Ideal Combination of Anti-Inflammatory and Anti-Viral Immune Activity, ResearchGate."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1002\/j.1460-2075.1986.tb04607.x","article-title":"Induction of anti-HIV neutralizing antibodies by synthetic peptides","volume":"5","author":"Chanh","year":"1986","journal-title":"EMBO J."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Millet, J.K., Kien, F., Cheung, C.-Y., Siu, Y.-L., Chan, W.-L., Li, H., Leung, H.-L., Jaume, M., Bruzzone, R., and Peiris, J.S.M. (2012). Ezrin Interacts with the SARS Coronavirus Spike Protein and Restrains Infection at the Entry Stage. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049566"},{"key":"ref_27","unstructured":"Holms, R.D. (1995). Aids Prophylactics. (Application No. PCT\/GB95\/001285), International Patent."},{"key":"ref_28","unstructured":"Holms, R.D. (2000). Regulatory\/Unfolding Peptides of Ezrin. (Application No. PCT\/GB00\/03566), International Patent."},{"key":"ref_29","unstructured":"Holms, R.D., and Ataullakhanov, R.I. (2004). HCV Combination Therapy. (Application No. PCT\/GB2004\/000330), International Patent."},{"key":"ref_30","unstructured":"Holms, R.D., and Ataullakhanov, R.I. (2006). The Use of Peptides In Anti-Ulcer Therapy. (Application No. PCT\/GB2006\/004390), International Patent."},{"key":"ref_31","unstructured":"Holms, R.D., Ataullakhanov, R.I., Ataullakhanov, R., and Sayadyan, K. (2016). Ezrin-Derived Peptides and Pharmaceutical Compositions Thereof. (Application No. PCT\/EP2016\/062336), International Patent."},{"key":"ref_32","unstructured":"(2021, August 13). Gepon\u2019 Preparation is Registered by the Russian Ministry of Health (Registration Documents R No: 000015\/01-2000 of 12.07.2000, FSP 42-0012-0015-00). The Instruction on the Medical Application of the \u2018Gepon\u2019 Preparation was Approved with the Decision of the Pharmacology Committee of the Ministry of Health of the Russian Federation (Minutes No: 8 of 7 October 1999). The Preparation Belongs to the Group of Immunomodulators and is Prescribed to Increase the Immune Defence Mechanism, to Treat and to Prevent Bacterial, Viral and Fungal Infections. Available online: https:\/\/avexima.ru\/medicines\/gepon\/."},{"key":"ref_33","unstructured":"(2021, August 13). Gepon Medical Instructions. Available online: https:\/\/295222.selcdn.ru\/avexima.ru\/iblock\/3d6\/3d60905d8aeaeaaf4f5c1fd5c1d77525\/f690b9c70c05d60181093820b56e5c07.pdf."},{"key":"ref_34","unstructured":"Ataullakhanov, R.I., Holms, R.D., Katlinsky, A.V., Pichugin, A.V., Papuashvili, M.N., and Shishkova, N.M. (2002). Treatment with Gepon immunomodulator increases the efficacy of the immune control of opportunistic infections in HIV-infected patients. Allergy Asthma Clin. Immunol., 3\u201311. (In Russian)."},{"key":"ref_35","unstructured":"Khaitov, R.M., and Ataullakhanov, R.I. (2011). Treatment of Acute Respiratory Disease and its Complications (Pneumonia). Chapter 7 Immunotherapy of Respiratory Disease. Section 2 Immunotherapy of Diseases of the Respiratory Tract. Immunotherapia, Izdatekskaya Group, GEOTAR-Media."},{"key":"ref_36","first-page":"138","article-title":"Effective treatment of Croup Syndrome with immunomodulator Gepon","volume":"147","author":"Kadova","year":"2002","journal-title":"Russ. Med. J."},{"key":"ref_37","unstructured":"Polyakova, T.O., Magomedov, M.M., Artemyev, M.E., Surikov, E.V., and Palchun, V.T. (2002). A new approach in the treatment of chronic diseases of the pharynx. Attend. Dr., 64\u201365. (In Russian)."},{"key":"ref_38","unstructured":"Kladova, O.V., Kharlamova, F.S., Shcherbakova, A.A., Legkova, T.P., Feldfix, L.I., Znamenskaya, A.A., Ovchinnikova, G.S., and Uchaikin, V.F. (2002). The first experience of Hepon intranasal application in children with respiratory infections. Pediatrics, 86\u201388. (In Russian)."},{"key":"ref_39","unstructured":"Kladova, O.V., and Uchiakin, V.F. Clinical Study Report on intranasal application of Gepon in children with the respiratory infections: Safety and efficacy of Gepon in Acute Respiratory Virus Infection [AVRI], Virus Induced Inflammation [VII], Laryngo-Tracheo-Bronchitis with Laryngeal Stenosis [SLTB] and Recurrent Croup [RC] syndrome, Unpublished."},{"key":"ref_40","first-page":"497","article-title":"Treatment of Hepatitis C Virus Infection with Human Ezrin Peptide One (HEP1) in HIV Infected Patients","volume":"57","author":"Salamov","year":"2007","journal-title":"Arzneim. Forschung Drug Res."},{"key":"ref_41","unstructured":"Gorbarets, I.P., Voronkova, N.V., Lopatina, T.V., Ivanovskaya, V.N., Braginsky, D.M., Blokhina, N.P., and Malyshev, N.A. (2003). The combined use of Hepon drug product and recombinant interferon-alpha in the patients with chronic hepatitis C increases the efficiency of antiviral treatment and reduces side effects of the therapy. Hepatology, 23\u201328. (In Russian)."},{"key":"ref_42","unstructured":"Cherednichenko, T.V., Uchaikin, V.F., Chaplygina, G.V., and Kurbanova, G.M. (2003). A new efficient treatment of viral hepatitis. Attend. Dr., 82\u201383. (In Russian)."},{"key":"ref_43","first-page":"90","article-title":"Treatment of patients with recurrent genital herpes","volume":"3","author":"Marchenko","year":"2004","journal-title":"Quest. Gynecol. Obstet. Perinatol."},{"key":"ref_44","unstructured":"Tishchenko, A.L. (2002). A new approach in the treatment of recurrent urogenital candidiasis. Attend. Dr., 46\u201347. (In Russian)."},{"key":"ref_45","first-page":"89","article-title":"Treatment of candidiasis in infants","volume":"3","author":"Telunts","year":"2004","journal-title":"Quest. Gynecol. Obstet. Perinatol."},{"key":"ref_46","unstructured":"Lazebnik, L.B., Zvenigorodskaya, L.A., Firsakova, V.Y., Pichugin, A.V., and Ataullakhanov, R.I. (2003). The application of Hepon immunomodulator in the treatment of erosive ulcerous lesions of gastroduodenal zone. Exp. Clin. Gastroenterol., 17\u201320. (In Russian)."},{"key":"ref_47","unstructured":"Malakhova, N.S., Pichugin, A.V., Khalif, I.L., and Ataullakhanov, R.I. (2005). The application of Hepon immunomodulator for the treatment of nonspecific ulcerative colitis. Farmateka, 105\u2013108. (In Russian)."},{"key":"ref_48","first-page":"646","article-title":"Treatment of local radiation injuries with the activator of local immunity","volume":"11","author":"Bardychev","year":"2003","journal-title":"Russ. Med. J."},{"key":"ref_49","unstructured":"Parfenov, A.I. (2003). The activator of the local immunity Hepon in the complex treatment of dysbiotic disorders of the intestine. Exp. Clin. Gastroenterol., 66\u201369. (In Russian)."},{"key":"ref_50","first-page":"1","article-title":"Biocenosis-protecting therapy of intestinal infections in children","volume":"6","author":"Novokshonov","year":"2004","journal-title":"Russ. Med. J."},{"key":"ref_51","unstructured":"Dudchenko, M.A., Lysenko, B.F., Chelishvili, A.L., Katlinsky, A.V., and Ataullakhanov, R.R. (2002). Complex treatment of trophic ulcers. Attend. Dr., 72\u201375. (In Russian)."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ejphar.2017.06.033","article-title":"Synthetic peptide TEKKRRETVEREKE derived from ezrin induces differentiation of NIH\/3T3 fibroblasts","volume":"811","author":"Chulkina","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_53","first-page":"9","article-title":"Amplification of antibody formation under the influence of immunomodulator Gepon","volume":"1","author":"Ataullakhanov","year":"2003","journal-title":"Immunlogy"},{"key":"ref_54","first-page":"12","article-title":"Immuno-adjuvant action of structural homologues of immunomodulator Gepon","volume":"1","author":"Katlinky","year":"2003","journal-title":"Immunology"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ortiz, A., and Serrador, J.M. (2020). ERM Proteins at the Crossroad of Leukocyte Polarization, Migration and Intercellular Adhesion. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041502"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0165-2478(96)02667-3","article-title":"Membrane-bound ezrin is involved in B-cell receptor-mediated signalling: Potential role of an ITAM-like ezrin motif","volume":"54","author":"Rozsnyayac","year":"1996","journal-title":"Immunol. Lett."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"a002360","DOI":"10.1101\/cshperspect.a002360","article-title":"The Cytoskeleton Coordinates the Early Events of B-cell Activation","volume":"3","author":"Harwood","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1084\/jem.20101125","article-title":"Dynamic cortical actin remodeling by ERM proteins controls BCR microcluster organization and integrity","volume":"208","author":"Treanor","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.bbamem.2013.07.016","article-title":"The pivotal position of the actin cytoskeleton in the initiation and regulation of B cell receptor activation","volume":"1838","author":"Song","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA)-Biomembr."},{"key":"ref_60","first-page":"138","article-title":"Immunomodulator Gepon: An Effective Treatment for Croup Syndrome","volume":"147","author":"Kladova","year":"2002","journal-title":"Russ. Med. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"170364","DOI":"10.1016\/j.peptides.2020.170364","article-title":"Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G+ granulocytes and Ly6C+ monocytes","volume":"132","author":"Chulkina","year":"2020","journal-title":"Peptides"},{"key":"ref_62","first-page":"17","article-title":"Change in cytokine gene transcription in human cells under the influence of immune-modulator Gepon","volume":"6","author":"Ataullakhanov","year":"2002","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_63","first-page":"3","article-title":"Immuno-modular Gepon enhances anti-body production","volume":"6","author":"Ataullakhanov","year":"2002","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_64","first-page":"308","article-title":"Development of Drugs Based on High-Polymeric Double-Stranded RNA for Antiviral and Antitumor Therapy","volume":"4","author":"Danilenk","year":"2019","journal-title":"Biochem. Suppl. Ser. B Biomed. Chem."},{"key":"ref_65","first-page":"30","article-title":"Antiviral activity of the peptide immunomodulator Gepon in experimental infections caused by herpes simplex virus types 1 and 2","volume":"5","author":"Barinsky","year":"2003","journal-title":"Probl. Virol."},{"key":"ref_66","unstructured":"(2021, August 13). Available online: https:\/\/www.abcam.com\/products?keywords=6F1A9++ab205381."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.3389\/fimmu.2018.03096","article-title":"The Coordination Between B Cell Receptor Signaling and the Actin Cytoskeleton During B Cell Activation","volume":"9","author":"Li","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.4049\/jimmunol.1001829","article-title":"The Role of the Transcription Factor CREB in Immune Function","volume":"185","author":"Wen","year":"2010","journal-title":"J. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/21\/11688\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:22:07Z","timestamp":1760167327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/21\/11688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":68,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ijms222111688"],"URL":"https:\/\/doi.org\/10.3390\/ijms222111688","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]}}}